I am starting to think that a lovenox reversal agent will garner a moderate amount of sales. I have had to cancel numerous invasive procedures due to the patient being on lovenox. This has led to patients staying in the hospital longer than need be. It seems every patient in the hospital goes on at least mini dose lovenox for DVT prophylaxis.
Thanks for weighing in. Are you saying that Lovenox use in this setting has increased, or rather that your awareness of Lovenox use in this setting has increased? Also, can you quantify what you mean by “mini dose Lovenox” in this context? Does the word mini as you’re using it refer to duration, or to the size of the doses? T.i.a.
UFH [reversal]—I'm not convinced as protamine is so cheap. Unless you give it rapidly the minor complication rate is very small. (Transient drop in blood pressure).
We’re on the same wavelength. I think some posters on this board have been hoodwinked about the market potential for UFH reversal. Regards, Dew
Unless you give it rapidly the minor complication rate is very small. (Transient drop in blood pressure).
From a recent Cochrane review:
Although being a relatively safe drug, it can cause severe systemic reactions with pronounced morbidity and mortality [1], and protamine sulfate is reported as one of the most common causes of life-threatening adverse reactions during cardiac surgery when used for rapid neutralization of heparin. Anaphylactic reactions to protamine sulfate have been known for many years, but the incidence reported varies from 0.06% to 10.6% [2] and range from minor haemodynamic instability to fatal cardiovascular collapse. The incidence of catastrophic reactions to protamine sulfate during cardiovascular surgery is reported to be 0.13% [3], and a recent study has con- ?rmed the relation between protamine sulfate reactions and mortality risk [4].
Reactions seem more common with diabetics that have received protamine-containing insulin, so maybe the current incidence is lower.